FCA: Forget chemoimmunotherapy with alemtuzumab?

Abstract

A randomized phase 3 trial conducted in France and Belgium shows that a chemoimmunotherapy consisting of fludarabine, cyclophosphamide, and alemtuzumab (FCA) causes an excess mortality and is less efficient compared with fludarabine, cyclophosphamide, and rituximab (FCR), the current standard therapy for physically fit patients with chronic lymphocytic leukemia (CLL). 1,2.